AU2010268389B2 - Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms - Google Patents

Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms Download PDF

Info

Publication number
AU2010268389B2
AU2010268389B2 AU2010268389A AU2010268389A AU2010268389B2 AU 2010268389 B2 AU2010268389 B2 AU 2010268389B2 AU 2010268389 A AU2010268389 A AU 2010268389A AU 2010268389 A AU2010268389 A AU 2010268389A AU 2010268389 B2 AU2010268389 B2 AU 2010268389B2
Authority
AU
Australia
Prior art keywords
cancer
expression
patient
macroh2a2
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010268389A
Other languages
English (en)
Other versions
AU2010268389A1 (en
AU2010268389A2 (en
Inventor
Andreas Ladurner
Thomas Muley
Judith Sporn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THORAXKLINIK-HEIDELBERG GGMBH
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
THORAXKLINIK HEIDELBERG GGMBH
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THORAXKLINIK HEIDELBERG GGMBH, Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical THORAXKLINIK HEIDELBERG GGMBH
Publication of AU2010268389A2 publication Critical patent/AU2010268389A2/en
Publication of AU2010268389A1 publication Critical patent/AU2010268389A1/en
Application granted granted Critical
Publication of AU2010268389B2 publication Critical patent/AU2010268389B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2010268389A 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms Ceased AU2010268389B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09008679A EP2270510A1 (en) 2009-07-02 2009-07-02 Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
EP09008679.4 2009-07-02
PCT/EP2010/004008 WO2011000573A1 (en) 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Publications (3)

Publication Number Publication Date
AU2010268389A2 AU2010268389A2 (en) 2012-01-12
AU2010268389A1 AU2010268389A1 (en) 2012-01-19
AU2010268389B2 true AU2010268389B2 (en) 2014-09-11

Family

ID=41100520

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010268389A Ceased AU2010268389B2 (en) 2009-07-02 2010-07-02 Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms

Country Status (11)

Country Link
US (1) US20120171225A1 (https=)
EP (2) EP2270510A1 (https=)
JP (1) JP5792165B2 (https=)
CN (1) CN102472753B (https=)
AU (1) AU2010268389B2 (https=)
BR (1) BRPI1011925A2 (https=)
CA (1) CA2766656A1 (https=)
ES (1) ES2681687T3 (https=)
SG (1) SG177398A1 (https=)
WO (1) WO2011000573A1 (https=)
ZA (1) ZA201109381B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
EP3546944A1 (en) * 2018-03-30 2019-10-02 Universite d'Aix-Marseille (AMU) Diagnosis and treatment of a cancer based on the overexpression of the adamtsl5 gene
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN111896740B (zh) * 2019-05-06 2025-02-11 山东大学 诊断或预测生育缺陷的试剂盒
CN119736252B (zh) * 2025-01-15 2025-06-27 首都医科大学 组蛋白变体macroH2A调控巨噬细胞功能在改善肿瘤免疫微环境中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148648A1 (en) * 2003-11-04 2007-06-28 Martin Dugas Method for distinguishing who classified aml subtypes
WO2009030770A2 (en) * 2007-09-07 2009-03-12 Universite Libre De Bruxelles Methods and tools for prognosis of cancer in er- patients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20050085628A1 (en) * 2002-01-31 2005-04-21 Kinya Yoda Production of hybridoma producing antihuman cenp-a peptide monoclonal antibody and method of using the same
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
CN100480382C (zh) * 2002-08-16 2009-04-22 抗癌公司 实时测量细胞反应
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
EP1640452A4 (en) * 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
WO2006119435A2 (en) * 2005-05-04 2006-11-09 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated proteins
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
EP1948215B1 (en) * 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
EP2145021A2 (en) * 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
JP2008292424A (ja) * 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
US20110224313A1 (en) * 2008-06-05 2011-09-15 British Columbia Cancer Agency Branch Compositions and methods for classifying lung cancer and prognosing lung cancer survival

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148648A1 (en) * 2003-11-04 2007-06-28 Martin Dugas Method for distinguishing who classified aml subtypes
WO2009030770A2 (en) * 2007-09-07 2009-03-12 Universite Libre De Bruxelles Methods and tools for prognosis of cancer in er- patients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Changolkar, L. N. et al., Molecular and Cellular Biology, 2007, Vol. 27, No. 7, pages 2758-2764 *
Pehrson, J. R. et al., Journal of Cellular Biochemistry, 1997, Vol. 65, pages 107-113 *

Also Published As

Publication number Publication date
EP2449383A1 (en) 2012-05-09
AU2010268389A1 (en) 2012-01-19
JP2012531612A (ja) 2012-12-10
AU2010268389A2 (en) 2012-01-12
EP2270510A1 (en) 2011-01-05
ES2681687T3 (es) 2018-09-14
WO2011000573A1 (en) 2011-01-06
ZA201109381B (en) 2012-08-29
CN102472753A (zh) 2012-05-23
EP2449383B1 (en) 2018-05-16
US20120171225A1 (en) 2012-07-05
CA2766656A1 (en) 2011-01-06
BRPI1011925A2 (pt) 2017-10-10
JP5792165B2 (ja) 2015-10-07
SG177398A1 (en) 2012-02-28
CN102472753B (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
US20110053156A1 (en) Small cell lung carcinoma biomarker panel
KR101976219B1 (ko) 유방암의 바이오마커
AU2010268389B2 (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroH2A isoforms
US20110257035A1 (en) Identification of signature genes associated with hepatocellular carcinoma
Ibusuki et al. Midkine in plasma as a novel breast cancer marker
KR20180100546A (ko) Parp 저해제를 이용한 소-세포성 폐암의 치료 방법
JP5224308B2 (ja) 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用
US20120028269A1 (en) Methods For Detection Of Gastric Cancer
Uemura et al. Current advances in esophageal cancer proteomics
US9005907B2 (en) Methods and compositions for typing molecular subgroups of medulloblastoma
JP7237587B2 (ja) マーカー、ヒト精巣上体タンパク質４（ｈｅ４）に基づく肺腺癌の再発を検出する方法および関連する使用
Hua et al. LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome
WO2010123124A1 (ja) 固形がんの再発および予後因子、およびその臨床利用
ES2896056T3 (es) PD-ECGF como biomarcador de cáncer
HK1170569B (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
HK1170569A (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
ES2743508T3 (es) Métodos y productos para el diagnóstico y el pronóstico de la malignidad de tumores de ovario
Lu et al. The expression of human epididymis protein 4 and cyclindependent kinase inhibitor p27Kip1 in human ovarian carcinoma
WO2019021654A1 (ja) 膵癌の予後マーカー、膵癌の予後診断キット及び膵癌の予後を予測するための方法
Sun et al. Functional screen for secreted proteins by monoclonal antibody library and

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 DEC 2011

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired